Emma Yates, CSO and co-founder of Campus-based Proteotype Diagnostics is an innovate UK Women in Innovation Award Winner

13/02/2025

Emma Yates, CSO and co-founder of Campus-based Proteotype Diagnostics is an innovate UK Women in Innovation Award Winner. Today, only 50% of cancers are detected early, largely because existing tests rely on detecting material shed by tumours, which only happens in advanced stages. Proteotype’s groundbreaking Enlighten test takes a different approach, measuring how the body’s immune system responds to cancer. This immune response is strongest in the earliest stages of cancer, enabling early detection. Their low-cost innovation could significantly increase early detection rates, lower mortality and allow for more personalised treatment strategies.

“Scientists often design approaches of ever-increasing complexity to create something new. I continually ask myself how I can approach the problem from a different angle and use creative solutions to bring simplicity and elegance,” says Emma.